USP 800 in Psychiatric Facilities
Registration Options
Activity Dates: 09/06/2018 - 09/06/2021
This course is closed. Please look for other available products in AAPP Education+Resources.
Target Audience
Pharmacists who handle HD preparations and work at facilities that store, prepare, transport, or administer HDs (e.g., pharmacies, hospitals or healthcare institutions, patient treatment clinics, physicians’ practice facilities, veterinarians’ offices).
Session Summary
The U.S. Pharmacopeial Convention (USP) has issued USP General Chapter <800> Hazardous Drug Handling in Healthcare Settings describing practice and quality standards for handling hazardous drugs (HDs) to promote patient safety, worker safety, and environmental protection. Handling HDs includes, but is not limited to, the receipt, storage, compounding, dispensing, administration, and disposal of sterile and nonsterile products and preparations. A psychiatric facility is unique in that the compounding of IV admixtures and the handling of antineoplastic drugs is extremely limited. Learn how to address the standards of USP 800 in a practical and effective manner that meets the needs of a psychiatric facility and balances the patient, worker and environmental safety with the needs for patient treatment.
Course Requirements
You will proceed through the following steps to satisfactorily complete this course:
- Sign in (or create a FREE account).
- Register for this course.
- Review the full content of the activity and reflect upon its teachings.
- Complete the post-test at the end of the activity no later than the closing activity date.
- Complete the evaluation at the end of the activity.
- If necessary, complete the post-test retest no later than the closing activity date.
- Receive a passing grade (70%).
- Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Participants in this course must complete an examination and achieve a score of 70% or greater. Successful completion of the course also requires the completion of a course evaluation. Upon successful completion, ACPE credit is reported immediately to CPE Monitor although transcripts can be retrieved by participants online at https://aapp.org/mycpnp/transcript/acpe.
AAPP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access AAPP course materials online, you will need:
- A modern web browser with JavaScript and cookies enabled: Chrome is strongly recommended, or the latest version of Firefox or Safari.
- A PDF reader: Chrome built-in, Firefox built-in, Acrobat or FoxIt
- An adequate device and Internet connection: Processor: Dual-core 2Ghz or higher (Intel i3/i5/i7 or AMD equivalent); Memory: 4 GB; Storage: 5 GB available; Internet speed: 4.0 Mbps (up/down)
AAPP web sites no longer fully support Microsoft Internet Explorer or Windows 8.1 and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.
Faculty Information and Disclosures
Ann Richards, PharmD, BCPP
View biographical information and disclosuresLearning Objectives
- Identify the criteria used to determine that a drug is hazardous.
- Describe processes used to identify hazardous drugs used within your facility.
- Develop an assessment of risk template that complies with USP 800.
- Discuss factors that influence the risk of exposure to a hazardous drug.
- Explain means to prevent exposure to hazardous drugs.
Continuing Education Credit and Disclosures
Activity Dates: 09/06/2018 - 09/06/2021ACPE Contact Hours: 1
ACPE Number: 0284-0000-18-050-H05-P (Knowledge)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This course provides 1.0 contact hours of knowledge-based continuing education credit from CPNP approved programming. The ACPE universal program number assigned to this course is 0284-0000-18-050-H05-P.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information and disclosures). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.